KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Accured Expenses: 2011-2024

Historic Change in Accured Expenses for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $18.3 million.

  • Esperion Therapeutics' Change in Accured Expenses rose 63.22% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 23.08%. This contributed to the annual value of $18.3 million for FY2024, which is 16.99% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Change in Accured Expenses of $18.3 million as of FY2024, which was down 16.99% from $22.1 million recorded in FY2023.
  • Esperion Therapeutics' 5-year Change in Accured Expenses high stood at $22.1 million for FY2023, and its period low was $2.8 million during FY2020.
  • Over the past 3 years, Esperion Therapeutics' median Change in Accured Expenses value was $18.3 million (recorded in 2024), while the average stood at $14.8 million.
  • In the last 5 years, Esperion Therapeutics' Change in Accured Expenses tumbled by 72.39% in 2020 and then spiked by 450.09% in 2023.
  • Over the past 5 years, Esperion Therapeutics' Change in Accured Expenses (Yearly) stood at $2.8 million in 2020, then surged by 150.85% to $6.9 million in 2021, then crashed by 42.00% to $4.0 million in 2022, then soared by 450.09% to $22.1 million in 2023, then fell by 16.99% to $18.3 million in 2024.